These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 12161475

  • 1. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [Abstract] [Full Text] [Related]

  • 2. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [Abstract] [Full Text] [Related]

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 4. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL, Amory JK, Berger R, Ugoni A, McLachlan RI, Bremner WJ.
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [Abstract] [Full Text] [Related]

  • 5. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
    Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM.
    J Androl; 1999 Jan; 20(3):407-14. PubMed ID: 10386821
    [Abstract] [Full Text] [Related]

  • 6. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
    Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM.
    J Androl; 2005 Jan; 26(3):405-13. PubMed ID: 15867009
    [Abstract] [Full Text] [Related]

  • 7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 8. Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men.
    Wang C, Wang XH, Nelson AL, Lee KK, Cui YG, Tong JS, Berman N, Lumbreras L, Leung A, Hull L, Desai S, Swerdloff RS.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):460-70. PubMed ID: 16278260
    [Abstract] [Full Text] [Related]

  • 9. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 10. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 11. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
    Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
    [Abstract] [Full Text] [Related]

  • 12. Suppression of human spermatogenesis by testosterone implants.
    Handelsman DJ, Conway AJ, Boylan LM.
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
    [Abstract] [Full Text] [Related]

  • 13. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men.
    Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J, Yang PJ, Gao ES.
    J Androl; 2004 Nov; 25(5):720-7. PubMed ID: 15292101
    [Abstract] [Full Text] [Related]

  • 14. Hormonal contraception in Chinese men: variations in suppression of spermatogenesis with injectable testosterone undecanoate and levonorgestrel implants.
    Liu ST, Gui YL, Lin CH, He CH.
    Asian J Androl; 2004 Mar; 6(1):41-6. PubMed ID: 15064833
    [Abstract] [Full Text] [Related]

  • 15. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 16. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception.
    Anderson RA, Kinniburgh D, Baird DT.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3640-9. PubMed ID: 12161488
    [Abstract] [Full Text] [Related]

  • 17. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
    McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
    [Abstract] [Full Text] [Related]

  • 18. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.
    Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E.
    Andrology; 2017 May; 5(3):516-526. PubMed ID: 28189123
    [Abstract] [Full Text] [Related]

  • 19. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men.
    Hair WM, Kitteridge K, O'Connor DB, Wu FC.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5201-9. PubMed ID: 11701677
    [Abstract] [Full Text] [Related]

  • 20. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.